LATOYA MOORE: Open Payments
NPI 1336884113 · LA PLACE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,444 in 70 payments from 10 companies in 2025. Trend: 2023 $1,454 · 2024 $1,450 · 2025 $1,444
Food & beverage: $1,444
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $325 |
| Supernus Pharmaceuticals, Inc. | 7 | $250 |
| ABBVIE INC. | 13 | $205 |
| E.R. Squibb & Sons, L.L.C. | 13 | $197 |
| Neurocrine BioSciences, Inc. | 7 | $161 |
| Janssen Pharmaceuticals, Inc | 3 | $79 |
| Alkermes, Inc. | 3 | $74 |
| Vanda Pharmaceuticals Inc. | 2 | $62 |
| Lundbeck LLC | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
Products named: Qelbree, VRAYLAR, COBENFY, REXULTI, ABILIFY ASIMTUFII, INGREZZA, INVEGA SUSTENNA, ARISTADA.
Industry payments across LA — which companies pay providers there.
